The acquisition of two partner-ready nanoparticle cancer candidates developed by Azaya Therapeutics Inc. and an associated nanotech platform could yield potential near-term revenue for Cytori Therapeutics Inc. as well as further-afield promise in the use of Azaya’s nanoparticle liposomal technology for the delivery of targeted regenerative therapies to sites of acute or chronic injury, the company said.